Category: biotech

.After revealing a period 3 launch based on positive midstage outcomes, iTeos and GSK are ultimately sharing the highlights from the phase 2 TIGIT trial,

.Otsuka Drug’s kidney health condition drug has reached the major endpoint of a period 3 trial through showing in an interim study the decrease of

.Bicara Therapies as well as Zenas Biopharma have actually delivered fresh incentive to the IPO market along with filings that illustrate what freshly public biotechs

.After rearing $213 thousand in 2023– among the year’s biggest exclusive biotech rounds– Tome Biosciences is actually creating cuts.” Regardless of our crystal clear medical

.OncoC4 is taking AcroImmune– and its internal medical manufacturing capabilities– under its wing in an all-stock merger.Both cancer cells biotechs were actually co-founded through OncoC4

.Zephyrm Bioscience is gusting towards the Hong Kong stock market, filing (PDF) for an IPO to money phase 3 trials of its tissue treatment in

.It is actually an abnormally busy Friday for biotech IPOs, along with Zenas BioPharma, MBX and Bicara Therapeutics all going community along with fine-tuned offerings.Of

.After disclosing plans to strike the U.S. public markets lower than a month ago, Zenas Biopharma and Bicara Therapies have mapped out the details behind

.Four months after Chinese genetics editing and enhancing company YolTech Rehabs took its own cholesterol disease-focused prospect into the center, Salubris Pharmaceuticals has safeguarded the

.Three months after uncovering that its own breathing syncytial infection (RSV) preventative antibody clesrovimab had passed inspection in a period 2b/3 test, Merck is putting